About: http://data.cimple.eu/news-article/37a0e7ebf6e8a0b71d425f390e43811c3a49e0bd19156ed79fe4290a

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/37a0e7ebf6e8a0b71d425f390e43811c3a49e0bd19156ed79fe4290a Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	French pharmaceutical giant Sanofi and American drugmaker Regeneron said Monday they have started clinical trials for a new drug in patients hospitalised with severe COVID-19 infections. In a statement they said phase 2 and 3 trials were under way for Kevzara, an immunosuppressor. Regeneron will trial in the United States, while Sanofi plans trials initially in Italy, particularly hard hit by the novel coronavirus pandemic. Kevzara, the brand name for sarilumab, an antibody that blocks the ability of some viruses to latch on to humane immune cells, has been in development since 2017. Specifically it inhibits the immune receptor that plays a key role in lung inflammation, something severe COVID-19 patients suffer from. Around 400 patients will take part in the studies, which will evaluated the effect of Kevzara on fever and oxygenation levels of patients. It will also look at how the drug works over the long term in reducing mortality rates, and potentially how it can reduce the need for respiratory apparatus in hospital. The number of novel coronavirus cases globally stood at 168,250 with 6,501 deaths, across 142 countries and territories at 0900 GMT Monday, according to an AFP tally based on official sources. lem/pg/txw
schema:headline	US, French firms start drug trial in severe COVID-19 cases
schema:mentions	Case fatality rate Immunosuppression Respiratory disease Inflammation Clinical trial Fever Medication French language Antibody Italy Pandemic United States Coronavirus Severe acute respiratory syndrome coronavirus 2 Immune receptor Sarilumab Sanofi Alpha-fetoprotein Greenwich Mean Time
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-03-16 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	82 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software